{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1361418519788094336.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1146/annurev-med-051013-110046"}},{"identifier":{"@type":"URI","@value":"https://www.annualreviews.org/doi/pdf/10.1146/annurev-med-051013-110046"}}],"dc:title":[{"@value":"The Mechanisms and Therapeutic Potential of SGLT2 Inhibitors in Diabetes Mellitus"}],"description":[{"type":"abstract","notation":[{"@value":"<jats:p> The kidneys in normoglycemic humans filter 160–180 g of glucose per day (∼30% of daily calorie intake), which is reabsorbed and returned to the systemic circulation by the proximal tubule. Hyperglycemia increases the filtered and reabsorbed glucose up to two- to three-fold. The sodium glucose cotransporter SGLT2 in the early proximal tubule is the major pathway for renal glucose reabsorption. Inhibition of SGLT2 increases urinary glucose and calorie excretion, thereby reducing plasma glucose levels and body weight. The first SGLT2 inhibitors have been approved as a new class of antidiabetic drugs in type 2 diabetes mellitus, and studies are under way to investigate their use in type 1 diabetes mellitus. These compounds work independent of insulin, improve glycemic control in all stages of diabetes mellitus in the absence of clinically relevant hypoglycemia, and can be combined with other antidiabetic agents. By lowering blood pressure and diabetic glomerular hyperfiltration, SGLT2 inhibitors may induce protective effects on the kidney and cardiovascular system beyond blood glucose control. </jats:p>"}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1381418519788094336","@type":"Researcher","foaf:name":[{"@value":"Volker Vallon"}],"jpcoar:affiliationName":[{"@value":"Division of Nephrology & Hypertension, Departments of Medicine and Pharmacology, University of California San Diego, La Jolla, California 92093;"},{"@value":"VA San Diego Healthcare System, San Diego, California 92161"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"00664219"},{"@type":"EISSN","@value":"1545326X"}],"prism:publicationName":[{"@value":"Annual Review of Medicine"}],"dc:publisher":[{"@value":"Annual Reviews"}],"prism:publicationDate":"2015-01-14","prism:volume":"66","prism:number":"1","prism:startingPage":"255","prism:endingPage":"270"},"reviewed":"false","url":[{"@id":"https://www.annualreviews.org/doi/pdf/10.1146/annurev-med-051013-110046"}],"createdAt":"2014-10-23","modifiedAt":"2021-10-14","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360283695654611200","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"SGLT2 Inhibitors as a Therapeutic Option for Diabetic Nephropathy"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567183439365504","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Effect of the sodium–glucose cotransporter 2 inhibitor luseogliflozin on pancreatic beta cell mass in db/db mice of different ages"}]},{"@id":"https://cir.nii.ac.jp/crid/1360579811554158592","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Postoperative Ketoacidosis With Hypoglycemia in a Nondiabetic Patient Taking Dapagliflozin for Heart Failure: A Case Report"}]},{"@id":"https://cir.nii.ac.jp/crid/1360580232408121216","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Sodium-glucose cotransporter 2 inhibitor-associated perioperative ketoacidosis: a systematic review of case reports"}]},{"@id":"https://cir.nii.ac.jp/crid/1360580232409248640","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Clinical Benefit of Switching from Low-Dose to High-Dose Empagliflozin in Patients with Type 2 Diabetes"}]},{"@id":"https://cir.nii.ac.jp/crid/1360846644399238656","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Dapagliflozin, a Sodium-Glucose Co-Transporter 2 Inhibitor, Acutely Reduces Energy Expenditure in BAT via Neural Signals in Mice"}]},{"@id":"https://cir.nii.ac.jp/crid/1360869855137386368","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Chronic kidney disease"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204244515200","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Kidney Cadmium Toxicity, Diabetes and High Blood Pressure: The Perfect Storm"}]},{"@id":"https://cir.nii.ac.jp/crid/1390003825194766848","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Empagliflozin's Ameliorating Effect on Plasma Triglycerides: Association with Endothelial Function Recovery in Diabetic Patients with Coronary Artery Disease"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679066036864","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"ja","@value":"哺乳類フルクトース輸送体GLUT5の構造と分子機構"},{"@language":"en","@value":"Structure and Molecular Mechanism of the Mammalian Fructose Transporter GLUT5"},{"@language":"ja-Kana","@value":"ホニュウルイ フルクトース ユソウタイ GLUT5 ノ コウゾウ ト ブンシ キコウ"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679610345344","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"The Sodium Glucose Cotransporter 2 Inhibitor Ipragliflozin Promotes Preferential Loss of Fat Mass in Non-obese Diabetic Goto–Kakizaki Rats"}]},{"@id":"https://cir.nii.ac.jp/crid/1390304029121103360","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Hamman Syndrome Caused by a Sodium Glucose Cotransporter 2 Inhibitor in an Elderly Patient with Diabetes Which Mimicked of Boerhaave Syndrome"}]},{"@id":"https://cir.nii.ac.jp/crid/1390576282592517760","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Efficacy of Low-dose Dapagliflozin in Young People with Type 1 Diabetes"}]},{"@id":"https://cir.nii.ac.jp/crid/1390845712980325504","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"The SGLT2 Inhibitor Dapagliflozin Significantly Improves the Peripheral Microvascular Endothelial Function in Patients with Uncontrolled Type 2 Diabetes Mellitus"}]},{"@id":"https://cir.nii.ac.jp/crid/1390848250124631040","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Synthesis and Structure–Activity Relationship of <i>C</i>-Phenyl D-Glucitol (TP0454614) Derivatives as Selective Sodium-Dependent Glucose Cotransporter 1 (SGLT1) Inhibitors"},{"@value":"Highlighted Paper selected by Editor-in-Chief : Synthesis and Structure-Activity Relationship of C-Phenyl D-Glucitol (TP0454614) Derivatives as Selective Sodium-Dependent Glucose Cotransporter 1 (SGLT1) Inhibitors"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1146/annurev-med-051013-110046"},{"@type":"CROSSREF","@value":"10.5551/jat.50807_references_DOI_4g2gaX2zbiaZnvIt6IzjGAuKmiq"},{"@type":"CROSSREF","@value":"10.1620/tjem.241.65_references_DOI_4g2gaX2zbiaZnvIt6IzjGAuKmiq"},{"@type":"CROSSREF","@value":"10.2169/internalmedicine.9632-22_references_DOI_4g2gaX2zbiaZnvIt6IzjGAuKmiq"},{"@type":"CROSSREF","@value":"10.3390/ijms18051083_references_DOI_4g2gaX2zbiaZnvIt6IzjGAuKmiq"},{"@type":"CROSSREF","@value":"10.2169/internalmedicine.0701-17_references_DOI_4g2gaX2zbiaZnvIt6IzjGAuKmiq"},{"@type":"CROSSREF","@value":"10.5940/jcrsj.58.133_references_DOI_4g2gaX2zbiaZnvIt6IzjGAuKmiq"},{"@type":"CROSSREF","@value":"10.1038/s41598-018-25126-z_references_DOI_4g2gaX2zbiaZnvIt6IzjGAuKmiq"},{"@type":"CROSSREF","@value":"10.1213/xaa.0000000000001570_references_DOI_4g2gaX2zbiaZnvIt6IzjGAuKmiq"},{"@type":"CROSSREF","@value":"10.1007/s00540-023-03174-8_references_DOI_4g2gaX2zbiaZnvIt6IzjGAuKmiq"},{"@type":"CROSSREF","@value":"10.1007/s13300-022-01296-y_references_DOI_4g2gaX2zbiaZnvIt6IzjGAuKmiq"},{"@type":"CROSSREF","@value":"10.1371/journal.pone.0150756_references_DOI_4g2gaX2zbiaZnvIt6IzjGAuKmiq"},{"@type":"CROSSREF","@value":"10.2169/internalmedicine.4327-24_references_DOI_4g2gaX2zbiaZnvIt6IzjGAuKmiq"},{"@type":"CROSSREF","@value":"10.1038/s41572-024-00589-9_references_DOI_4g2gaX2zbiaZnvIt6IzjGAuKmiq"},{"@type":"CROSSREF","@value":"10.1248/cpb.c20-00089_references_DOI_4g2gaX2zbiaZnvIt6IzjGAuKmiq"},{"@type":"CROSSREF","@value":"10.1248/bpb.b16-00964_references_DOI_4g2gaX2zbiaZnvIt6IzjGAuKmiq"}]}